Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Marie Boumans"'
Autor:
Paul L. Klarenbeek, Rogier M Thurlings, A. H. C. van Kampen, Marieke E. Doorenspleet, Danielle M. Gerlag, R.E. Esveldt, Koen Vos, Frank Baas, Sabrina Pollastro, P.P. Tak, B D C van Schaik, N. de Vries, Marie Boumans
Publikováno v:
THURSDAY, 14 JUNE 2018.
Background Rituximab (RTX) induces more than 98% depletion of the CD20 +B cells in blood after a single injection, yet 35% to 50% of RA treated patients show a poor response to the therapy1. Despite the identification of many different biomarkers, mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03987c0fb3455f458a75956350f1d0c0
https://doi.org/10.1136/annrheumdis-2018-eular.7072
https://doi.org/10.1136/annrheumdis-2018-eular.7072
Autor:
Rogier M, Thurlings, Marie, Boumans, Janneke, Tekstra, Joel A, van Roon, Koen, Vos, Daisy Marie, van Westing, Lisa G, van Baarsen, Carina, Bos, Kyriakos A, Kirou, Danielle M, Gerlag, Mary K, Crow, Johannes W, Bijlsma, Cornelis L, Verweij, Paul P, Tak
Publikováno v:
Arthritis and rheumatism. 62(12)
To analyze the relationship between the type I interferon (IFN) signature and clinical response to rituximab in rheumatoid arthritis (RA) patients.Twenty RA patients were treated with rituximab (cohort 1). Clinical response was defined as a decrease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::72f19f25648af4a25af73aa40af21a0c
https://pubmed.ncbi.nlm.nih.gov/21882169
https://pubmed.ncbi.nlm.nih.gov/21882169
Autor:
J.A. van Roon, Rogier M Thurlings, Frank A. Redegeld, Koen Vos, J. W. J. Bijlsma, Janneke Tekstra, P. P. Tak, F.P.J.G. Lafeber, T. Groot Kormelink, Marie Boumans
Publikováno v:
Annals of the rheumatic diseases, 69(12), 2137-2144. BMJ Publishing Group
Annals of the Rheumatic Diseases, 69(12), 2137-2144. BMJ Publishing Group
Annals of the Rheumatic Diseases, 69(12), 2137-2144. BMJ Publishing Group
ObjectivesImmunoglobulin (Ig) free light chains (FLCs) are short-lived B cell products that contribute to inflammation in several experimental disease models. In this study, FLC concentrations in inflamed joints of patients with rheumatoid arthritis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25b65f9b0b761539c01f2102071185b8
https://pubmed.ncbi.nlm.nih.gov/20679475
https://pubmed.ncbi.nlm.nih.gov/20679475
Autor:
Rogier M Thurlings, Marie Boumans, W J de Jager, Koen Vos, Daisy Marie van Westing, Lisa G van Baarsen, Danielle M Gerlag, B Prakken, Paul P Tak
Publikováno v:
Annals of the Rheumatic Diseases. 73:A32.1-A32
Background and Objectives Rituximab aims to deplete CD20 positive B cells and exerts a significant and often long-lasting clinical effect in a subset of patients with rheumatoid arthritis (RA). The extent of B cell depletion in the inflammatory tissu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6384835d4c3fa259c7feac35096f1cb
https://doi.org/10.1136/annrheumdis-2013-205124.72
https://doi.org/10.1136/annrheumdis-2013-205124.72
Autor:
Marie Boumans, B D C van Schaik, Danielle M. Gerlag, Paul L. Klarenbeek, Rogier M. Thurlings, Marieke E. Doorenspleet, N. de Vries, R.E. Esveldt, Robert M. Plenge, A. H. C. van Kampen, Frank Baas, PP Tak
Publikováno v:
Annals of the Rheumatic Diseases. 71:313.3-313
Background Autoreactive B-lymphocytes are thought to play an important role in rheumatoid arthritis (RA). B-cell depletion therapy by rituximab (RTX) has shown that targeting the humoral immune response can result in clinical improvement. Unfortunate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e97e684e997722a9b4f3e131a4dfdce8
https://doi.org/10.1136/annrheumdis-2012-eular.2467
https://doi.org/10.1136/annrheumdis-2012-eular.2467